Genovate Biotechnology Co Ltd (4130) — Capital Reinvestment Ratio
Genovate Biotechnology Co Ltd (4130) has a Capital Reinvestment Ratio of 0.48x as of December 2025, meaning it reinvests 0% of its operating cash flow (NT$16.93 Million) in capital expenditures (NT$8.19 Million). Check tangible net worth ratio of Genovate Biotechnology Co Ltd to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Genovate Biotechnology Co Ltd Capital Reinvestment Ratio (2015–2025)
This chart tracks Genovate Biotechnology Co Ltd's Capital Reinvestment Ratio across 10 annual periods. For the full cash flow conversion analysis, see Genovate Biotechnology Co Ltd (4130) cash flow conversion.
Annual Capital Reinvestment Ratio for Genovate Biotechnology Co Ltd (2015–2025)
Year-by-year Capital Reinvestment Ratio for Genovate Biotechnology Co Ltd from 2015 to 2025. See cash generation quality of Genovate Biotechnology Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.40x | NT$43.79 Million | NT$61.42 Million | ▲ +146.4% |
| 2024 | 0.57x | NT$55.11 Million | NT$31.37 Million | ▲ +44.7% |
| 2023 | 0.39x | NT$84.78 Million | NT$33.34 Million | ▼ -97.5% |
| 2022 | 15.90x | NT$1.51 Million | NT$24.01 Million | ▲ +5026.6% |
| 2020 | 0.31x | NT$87.08 Million | NT$27.01 Million | ▼ -46.5% |
| 2019 | 0.58x | NT$44.43 Million | NT$25.76 Million | ▲ +3.4% |
| 2018 | 0.56x | NT$62.88 Million | NT$35.26 Million | ▼ -54.5% |
| 2017 | 1.23x | NT$31.27 Million | NT$38.53 Million | ▲ +112.8% |
| 2016 | 0.58x | NT$70.58 Million | NT$40.87 Million | ▼ -65.0% |
| 2015 | 1.65x | NT$32.53 Million | NT$53.75 Million | — |